R-932348

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameR-932348
Drug Alias NameR-932348R-348
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSpleen tyrosine kinase inhibitorsTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK3Spleen tyrosine kinase
Therapy Area/IndicationsGraft vs Host DiseaseKeratoconjunctivitis Sicca
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRigel Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRigel Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsGraft vs Host DiseaseKeratoconjunctivitis Sicca

Other Information

ATC CodeN/A
Related LinksN/A